Trial Profile
A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics of Apalutamide in Subjects With Severe Hepatic Impairment Compared With Subjects With Normal Hepatic Function
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary)
- Indications Prostate cancer; Salivary gland cancer
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 05 Dec 2023 Planned End Date changed from 30 Dec 2024 to 31 May 2024.
- 05 Dec 2023 Planned primary completion date changed from 3 Jun 2024 to 31 May 2024.
- 22 Nov 2022 Planned primary completion date changed from 14 Oct 2022 to 3 Jun 2024.